Evidence map›Paper›PMID 32533363›Full record

ArticleHuman genetics2020

Study of telomere length in men who carry a fragile X premutation or full mutation allele.

Igor Albizua, Pankaj Chopra, Emily G Allen, Weiya He, Ashima S Amin, Stephanie L Sherman

Open access · greenAbstract read
In one paragraph

Article in Human genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Igor AlbizuaDepartment of Human Genetics, Emory University School of Medicine, 615 Michael Street, Suite 325.1, Atlanta, GA, 30322, USA. ialbizu@emory.edu.ORCID http://orcid.org/0000-0002-8675-1352
Pankaj ChopraDepartment of Human Genetics, Emory University School of Medicine, 615 Michael Street, Suite 325.1, Atlanta, GA, 30322, USA.
Emily G AllenDepartment of Human Genetics, Emory University School of Medicine, 615 Michael Street, Suite 325.1, Atlanta, GA, 30322, USA.
Weiya HeDepartment of Human Genetics, Emory University School of Medicine, 615 Michael Street, Suite 325.1, Atlanta, GA, 30322, USA.
Ashima S AminDepartment of Human Genetics, Emory University School of Medicine, 615 Michael Street, Suite 325.1, Atlanta, GA, 30322, USA.
Stephanie L ShermanDepartment of Human Genetics, Emory University School of Medicine, 615 Michael Street, Suite 325.1, Atlanta, GA, 30322, USA.
Emory University · US

Funding

Recruitment CoreU54NS091859 · NINDS · EMORY UNIVERSITY · PI WARREN, STEPHEN T. · 2014 to 2019
$9.1M
Eunice Kennedy Shriver National Institute of Child Health and Human Development NS091859NINDS NIH HHS U54 NS091859
6 · The paper itself

Abstract

The fragile X premutation is defined by the expansion of the CGG trinucleotide repeat at the 5' UTR of the FMR1 gene to between 55 and 200 repeats, while repeat tracks longer than 200 are defined as full mutations. Men carrying a premutation are at increased risk for fragile X-associated tremor/ataxia syndrome (FXTAS); those with > 200 repeats have fragile X syndrome, a common genetic form of intellectual disabilities. In our study, we tested the hypothesis that men carrying a fragile X premutation or full mutation are "biologically older", as suggested by the associated age-related disorder in the presence of the fragile X premutation or the altered cellular pathology that affects both the fragile X premutation and full mutation carriers. Thus, we predicted that both groups would have shorter telomeres than men carrying the normal size repeat allele. Using linear regression models, we found that, on average, premutation carriers had shorter telomeres compared with non-carriers (n = 69 vs n = 36; p = 0.02) and that there was no difference in telomere length between full mutation carriers and non-carriers (n = 37 vs n = 29; p > 0.10). Among premutation carriers only, we also asked whether telomere length was shorter among men with vs without symptoms of FXTAS (n = 28 vs n = 38 and n = 27 vs n = 41, depending on criteria) and found no evidence for a difference (p > 0.10). Previous studies have shown that the premutation is transcribed whereas the full mutation is not, and the expanded repeat track in FMR1 transcript is thought to lead to the risk for premutation-associated disorders. Thus, our data suggest that the observed premutation-only telomere shortening may be a consequence of the toxic effect of the premutation transcript and suggest that premutation carriers are "biologically older" than men carrying the normal size allele in the same age group.

Indexed as

5' Untranslated RegionsAdultAgedAllelesAtaxiaFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeHumansMaleMiddle AgedMutationTelomereTelomere HomeostasisTremorTrinucleotide Repeat ExpansionYoung Adult5' Untranslated RegionsFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1

Identifiers

PMID32533363
PMCPMC8494119
OpenAlexW3034704171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.